Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The revenues this quarter are in line with the outlook we envisaged for the year
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Subscribe To Our Newsletter & Stay Updated
